Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation ratios exhibit considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial stability in the first three quarters of 2022 gives way to significant volatility, particularly noticeable in the latter half of 2024 and the first half of 2025. A general upward trend is apparent in most ratios towards the end of the period, though the magnitude of change varies considerably between them.
- Price to Earnings (P/E) Ratio
- The P/E ratio remained relatively contained between 17.25 and 29.30 from March 2022 through December 2022. A dramatic increase is observed in March 2024, reaching 166.76, followed by a substantial decline and subsequent increase, culminating in a value of 21.54 by December 2025. This suggests significant shifts in investor expectations regarding future earnings.
- Price to Operating Profit (P/OP) Ratio
- Similar to the P/E ratio, the P/OP ratio demonstrated relative stability in 2022, ranging from 10.78 to 16.27. A pronounced surge occurs in March 2024 (51.26), mirroring the P/E ratio’s behavior, and is followed by a similar pattern of decline and recovery, ending at 18.29 in December 2025. This correlation indicates a strong relationship between market valuation and operating profitability.
- Price to Sales (P/S) Ratio
- The P/S ratio exhibited a more gradual increase throughout the period. Starting around 2.86 in early 2022, it generally trended upward, with fluctuations, to reach 6.34 by December 2025. The increases in late 2024 and early 2025 are less dramatic than those seen in the P/E and P/OP ratios, suggesting a more consistent, albeit growing, valuation relative to revenue.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio showed a consistent upward trend, though with some variability. Beginning at 3.91 in March 2022, it increased to 8.07 by December 2025. This indicates a growing premium placed on the company’s net asset value over time. The increases are relatively steady, without the sharp spikes observed in the earnings and operating profit multiples.
The pronounced increases in the P/E and P/OP ratios in March 2024, followed by subsequent corrections, warrant further investigation to understand the underlying drivers of these valuation shifts. The consistent upward trend in the P/S and P/BV ratios suggests a long-term increase in the market’s assessment of the company’s revenue generation and asset base.
Price to Earnings (P/E)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Net income (loss) attributable to Gilead (in millions) | |||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
EPS
= (Net income (loss) attributable to GileadQ4 2025
+ Net income (loss) attributable to GileadQ3 2025
+ Net income (loss) attributable to GileadQ2 2025
+ Net income (loss) attributable to GileadQ1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The price-to-earnings (P/E) ratio exhibited considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a moderate valuation, followed by periods of significant volatility and, ultimately, a return to more moderate levels.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The P/E ratio began at 17.25 and demonstrated a generally increasing trend through the end of 2022, peaking at 29.30 in September before decreasing to 22.68 by December. This suggests increasing investor optimism during this period, potentially driven by earnings performance, followed by a slight correction.
- Early 2023 (Mar 31, 2023 – Jun 30, 2023)
- The first half of 2023 saw the P/E ratio stabilize in the mid-to-high teens, fluctuating between 17.75 and 17.88. This indicates a period of relative valuation consistency, aligning with stable earnings per share.
- Significant Volatility (Mar 31, 2024 – Dec 31, 2024)
- A dramatic increase in the P/E ratio occurred in the first half of 2024, reaching an exceptionally high value of 925.87 in September. This surge coincided with a substantial decrease in earnings per share, indicating a significant disconnect between price and earnings. The ratio then decreased to 296.57 by the end of the year, but remained elevated. This period suggests a potential overvaluation or market speculation.
- Recent Period (Mar 31, 2025 – Dec 31, 2025)
- The P/E ratio decreased substantially in the latter half of 2025, falling to 21.54 by December. This decline appears to be correlated with an increase in earnings per share, suggesting a return towards a more reasonable valuation. The ratio fluctuated between 20.62 and 21.68 in the first half of 2025, before increasing to 18.18 in September and then 21.54 by the end of the year.
Overall, the P/E ratio demonstrated a cyclical pattern with periods of stability punctuated by significant swings. The extreme values observed in 2024 warrant further investigation to understand the underlying market dynamics and earnings drivers. The recent trend suggests a potential normalization of the valuation as earnings have increased.
Price to Operating Profit (P/OP)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Operating income (loss) (in millions) | |||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Operating profit per share
= (Operating income (loss)Q4 2025
+ Operating income (loss)Q3 2025
+ Operating income (loss)Q2 2025
+ Operating income (loss)Q1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The Price to Operating Profit (P/OP) ratio for the analyzed period demonstrates considerable fluctuation. Initially, the ratio exhibited a generally increasing trend from March 2022 to September 2022, followed by a decline through December 2022. A significant spike occurred in the first half of 2024, followed by a substantial decrease and subsequent recovery towards the end of the observed period.
- Initial Phase (Mar 31, 2022 – Sep 30, 2022)
- The P/OP ratio increased from 10.78 to 16.27. This suggests that the market was willing to pay a progressively higher premium for each dollar of operating profit during this timeframe. The increase could be attributed to positive investor sentiment or expectations of future growth.
- Decline (Dec 31, 2022 – Mar 31, 2023)
- A downward trend was observed, with the P/OP ratio decreasing from 14.21 to 11.21. This indicates a lessening of investor enthusiasm or a reassessment of the company’s profitability prospects.
- Volatility and Peak (Apr 01, 2024 – Sep 30, 2024)
- The P/OP ratio experienced extreme volatility, rising dramatically from 51.26 to 143.05 before falling to 0.66. This period is characterized by a significant disconnect between share price and operating profit, potentially driven by speculative trading, market events, or unique company-specific news. The subsequent drop to 0.66 suggests a substantial correction or negative market reaction.
- Recovery and Stabilization (Oct 01, 2024 – Dec 31, 2025)
- Following the sharp decline, the P/OP ratio began to recover, reaching 18.29 by December 31, 2025. This recovery suggests a restoration of investor confidence and a more reasonable valuation relative to operating profit. The ratio remained relatively stable in the latter half of 2025, indicating a period of consolidation.
- Operating Profit per Share Influence
- Fluctuations in the operating profit per share metric directly influence the P/OP ratio. Periods of increasing operating profit per share generally coincide with lower P/OP ratios, and vice versa, although the share price component introduces significant variability. The dramatic changes in the P/OP ratio in 2024 are not solely attributable to changes in operating profit per share, highlighting the influence of market sentiment and external factors.
Overall, the P/OP ratio demonstrates a complex pattern over the analyzed period. While initial trends suggest a stable or increasing valuation, the period from 2024 onwards is marked by significant volatility and a subsequent recovery. The ratio’s behavior indicates a sensitivity to both company performance and broader market dynamics.
Price to Sales (P/S)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Product sales (in millions) | |||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Sales per share
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The price-to-sales (P/S) ratio exhibited fluctuating behavior over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable ratio, followed by a period of increase, and then a subsequent decline before rising again towards the end of the period.
- Initial Period (Mar 31, 2022 – Jun 30, 2022)
- The P/S ratio remained remarkably consistent, fluctuating minimally between 2.86 and 2.84. This suggests a period of equilibrium between share price and sales per share.
- Ascending Trend (Sep 30, 2022 – Dec 31, 2022)
- An upward trend became apparent, with the P/S ratio increasing from 3.64 to 3.86. This increase indicates that the share price grew at a faster rate than sales per share during this timeframe.
- Subsequent Decline (Mar 31, 2023 – Dec 31, 2023)
- Following the peak in December 2022, the P/S ratio experienced a decline, reaching a low of 3.40 in December 2023. This suggests a period where share price growth moderated or sales per share increased at a faster pace.
- Resurgence and Peak (Mar 31, 2024 – Dec 31, 2025)
- The P/S ratio demonstrated a significant resurgence, climbing from 2.97 to a high of 6.34 by December 2025. This substantial increase indicates a considerable appreciation in the share price relative to sales per share. The rate of increase accelerated in the latter half of 2025.
Throughout the period, sales per share demonstrated a generally increasing trend, albeit with minor fluctuations. This upward trajectory in sales per share likely contributed to the overall changes observed in the P/S ratio, interacting with the share price movements to produce the observed patterns.
The most pronounced change occurred in the final year of the observed period, with a substantial increase in the P/S ratio. This suggests a shift in investor sentiment or a significant change in growth expectations relative to sales.
Price to Book Value (P/BV)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Total Gilead stockholders’ equity (in millions) | |||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The price-to-book value (P/BV) ratio for the analyzed period demonstrates considerable fluctuation. Initially, the ratio exhibited a moderate increase from 3.91 to 4.90 between March 31, 2022, and December 31, 2022. This was followed by a decline to a low of 4.01 by December 31, 2023. A significant upward trend then emerged, culminating in a ratio of 8.07 as of December 31, 2025.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The P/BV ratio increased steadily during this period, suggesting a growing investor confidence in the company’s ability to generate value relative to its book value. The increase, while present, remained within a relatively narrow range.
- Subsequent Decline (Dec 31, 2022 – Dec 31, 2023)
- A noticeable decrease in the P/BV ratio occurred over the subsequent year. This decline could indicate a shift in market perception, potentially due to concerns about future earnings or a reassessment of the company’s asset value. The ratio’s movement suggests the market was valuing the company’s net asset value less optimistically.
- Recent Increase (Dec 31, 2023 – Dec 31, 2025)
- The most recent period is characterized by a substantial increase in the P/BV ratio. This suggests a renewed positive market sentiment, potentially driven by improved financial performance, positive industry developments, or anticipated future growth. The ratio more than doubled over this timeframe, indicating a significant premium placed on the company’s net assets.
- Book Value per Share (BVPS) Trend
- Book value per share generally increased from $15.89 to $18.33 between March 31, 2022, and December 31, 2023. However, it experienced a decrease to $14.08 by March 31, 2024, before resuming an upward trend, reaching $18.29 by December 31, 2025. The fluctuations in BVPS contribute to the overall changes observed in the P/BV ratio, but the P/BV ratio’s movements are more pronounced, indicating the share price is the primary driver of the observed trends.
In summary, the P/BV ratio has demonstrated a cyclical pattern over the analyzed period, with phases of growth, decline, and substantial recent expansion. The ratio’s recent increase warrants further investigation to determine the underlying factors driving this positive market sentiment.